Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis.
Calvat P, Leung C, Bost C, Fortenfant F, Simonetta-Moreau M, Pariente J, Rafiq M, Brefel-Courbon C, Rascol O, Fabbri M, Ory-Magne F. Calvat P, et al. Among authors: rascol o. Parkinsonism Relat Disord. 2023 Feb;107:105232. doi: 10.1016/j.parkreldis.2022.105232. Epub 2022 Dec 7. Parkinsonism Relat Disord. 2023. PMID: 36509623 No abstract available.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
Reply to: "What Is in a Name".
Brefel-Courbon C, Marques A, Rascol O; NS‐Park OXYDOPA study group. Brefel-Courbon C, et al. Among authors: rascol o. Mov Disord. 2024 Sep;39(9):1652-1653. doi: 10.1002/mds.29944. Mov Disord. 2024. PMID: 39441144 No abstract available.
Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.
Ferreira JJ, Lee JY, Ma HI, Jeon B, Poewe W, Antonini A, Stocchi F, Rodrigues DM, Fonseca MM, Castilla-Fernández G, Holenz J, Rocha JF, Rascol O; ADOPTION study investigators. Ferreira JJ, et al. Among authors: rascol o. J Neurol. 2024 Oct;271(10):6729-6738. doi: 10.1007/s00415-024-12614-8. Epub 2024 Aug 21. J Neurol. 2024. PMID: 39164557 Free PMC article. Clinical Trial.
Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
Brefel-Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, Ory-Magne F, Fabbri M, Maltête D, Rouaud T, Drapier S, Tir M, Thobois S, Salhi H, Corvol JC, Castelnovo G, Lagha-Boukbiza O, Fluchère F, Frismand S, Ansquer S, Sommet A, Rascol O. Brefel-Courbon C, et al. Among authors: rascol o. Mov Disord. 2024 Sep;39(9):1533-1543. doi: 10.1002/mds.29878. Epub 2024 Jun 8. Mov Disord. 2024. PMID: 38850081 Clinical Trial.
Skull Density Ratio as Arm-Allocation Parameter for a Controlled Focused Ultrasound Trial in Parkinson's Disease.
Pineda-Pardo JA, Martínez-Fernández R, Natera-Villalba E, Ruiz-Yanzi A, Rodríguez-Rojas R, Del Alamo M, Jiménez-Castellanos T, Matarazzo M, Gasca-Salas C, Rascol O, Obeso JA. Pineda-Pardo JA, et al. Among authors: rascol o. Mov Disord Clin Pract. 2024 Jul;11(7):825-829. doi: 10.1002/mdc3.14040. Epub 2024 May 13. Mov Disord Clin Pract. 2024. PMID: 38741245 Free PMC article.
595 results